Spots Global Cancer Trial Database for Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
Official Title: A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Study ID: NCT05553808
Conditions
Study Description
Brief Summary: This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Saint Louis, Missouri, United States
GSK Investigational Site, Nashville, Tennessee, United States
GSK Investigational Site, Dallas, Texas, United States
GSK Investigational Site, Toronto, Ontario, Canada
GSK Investigational Site, Bordeaux Cedex, , France
GSK Investigational Site, Caen Cedex 9, , France
GSK Investigational Site, Nantes cedex 1, , France
GSK Investigational Site, Paris Cedex 05, , France
GSK Investigational Site, Paris, , France
GSK Investigational Site, Villejuif Cedex, , France
GSK Investigational Site, Gauting, Bayern, Germany
GSK Investigational Site, Immenhausen, Hessen, Germany
GSK Investigational Site, Leipzig, Sachsen, Germany
GSK Investigational Site, Grosshansdorf, Schleswig-Holstein, Germany
GSK Investigational Site, Berlin, , Germany
GSK Investigational Site, Meldola (FC), Emilia-Romagna, Italy
GSK Investigational Site, Ravenna, Emilia-Romagna, Italy
GSK Investigational Site, Milano, Lombardia, Italy
GSK Investigational Site, Orbassano (TO), Piemonte, Italy
GSK Investigational Site, Cheongju-si, , Korea, Republic of
GSK Investigational Site, Gyeonggi-do, , Korea, Republic of
GSK Investigational Site, Seongnam, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Maastricht, , Netherlands
GSK Investigational Site, Lodz, , Poland
GSK Investigational Site, Poznan, , Poland
GSK Investigational Site, Warszawa, , Poland
GSK Investigational Site, Bucharest, , Romania
GSK Investigational Site, Craiova, , Romania
GSK Investigational Site, Floresti, , Romania
GSK Investigational Site, Otopeni, , Romania
GSK Investigational Site, Timisoara, , Romania
GSK Investigational Site, Chelyabinsk, , Russian Federation
GSK Investigational Site, Saint-Petersburg, , Russian Federation
GSK Investigational Site, Saint-Petersburg, , Russian Federation
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Santander, , Spain
GSK Investigational Site, Sevilla, , Spain
GSK Investigational Site, Uppsala, , Sweden
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
